This invention is for a method of genetic modification of major histocompatibility complex (MCH) component for prevention of natural killer (NK) cell recognition of pluripotent stem cell grafts using HLA-C trimers. This new method works to overcome immunological rejection by the recipient via genetic modification of these cells. Background: As of 2020, there were more than 3,000 trials involving the use of adult stem cells registered in WHO International Clinical Trials Registry. Induced pluripotent stem cell therapy is a novel medical therapy that utilizes donor embryonic stem cells capable of differentiating into a multitude of different cells throughout the body. Despite the variability of these cells, immunological resistance is persistent in a variety of patients. This innovation focuses on a solution for the regulation and limitation of recognition tendencies of NK cells, ultimately offering a means to generate a strategy for engineering universal human PSCs (hPSCs) for the treatment of a variety of diseases. Applications:
Advantages: